O02 SIMULTANEOUS BLOOD PRESSURE AND ATRIAL FIBRILLATION SCREENING IN MAY MEASUREMENT MONTH 2022

Background and objective: May Measurement Month (MMM) is a global campaign aiming to raise awareness of raised blood pressure (BP). In 2022, concurrent screening for BP and atrial fibrillation (AF) was conducted in ten countries, given that hypertension and AF are both major treatable risk factors for stroke. Here, we evaluate AF prevalence and treatment by BP status among opportunistic samples of adults. Methods: In MMM, adults (≥18 years) undergo opportunistic BP screening. In ten participating countries, concurrent AF screening was carried out using OMRON Complete or M7 devices, in addition to three standardized, sitting BP measurements. ‘Known’ AF was defined as having had a previous diagnosis of either AF or irregular heartbeat, or taking oral anticoagulants. To risk-stratify those with AF, we calculated the CHA2DS2-VASc score. Hypertension was defined as a BP ≥140 and/or ≥90 mmHg (average of the second and third readings) and/or taking BP-lowering medication. Results: 80,751 adults (mean age 50.1 years; 58.2% female) underwent BP and AF screening. AF was detected in 1,526 (1.9%), of whom 1,014 (66.4%) had ‘known’ AF. Of those with ‘known’ AF, 214 (21.1%) were taking anticoagulants and 644 (63.5%) were taking neither anticoagulants nor aspirin. AF was detected more commonly among those aged ≥60 than <60 (3.2% vs 1.2%: p<0.001). Hypertension was detected more commonly among those with than without AF (63.6% vs 45.2%; age-sex-adjusted p<0.001). There was a graded association in anticoagulant and aspirin treatment rates according to CHA2DS2-VASc score in participants with ‘known’ AF (Table). Amongst participants with ‘known’ AF, anticoagulant usage was reported by 35.7% of those with a class 1 indication for anticoagulation according to CHA2DS2-VASc score. Conclusions Opportunistic AF screening in the MMM 2022 campaign detected AF in 3.2% of participants aged ≥60, and hypertension was more common in those with AF. Over one third of detected cases were not ‘known’ cases. Only 35.7% of ‘known’ cases with a class 1 indication for anticoagulants were treated.